KUKuang

Kuang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kuang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Fan

    Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science

    1 shared publication
  • Junyi Hu

    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    1 shared publication
  • Ke Chen

    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Lilong Liu

    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Yang Li

    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    1 shared publication
  • Yao

    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    1 shared publication

Latest Publications

  • Open Access

    An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG to assess prognosis and immunotherapy response in bladder cancer patients

    by Lilong Liu, Zhenghao Liu, Lei Fan, Zhipeng Yao, Junyi Hu, Yaxin Hou, Yang Li, Yuhong Ding, Yingchun Kuang, Ke Chen, et al.

    Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses that can reshape the tumor microenvironment. Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. The Cancer Genome Atlas (TCGA) BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival. This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.